HomeCompareHWAFF vs PFE

HWAFF vs PFE: Dividend Comparison 2026

HWAFF yields 241.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HWAFF wins by $18955150364549300.00M in total portfolio value
10 years
HWAFF
HWAFF
● Live price
241.67%
Share price
$0.24
Annual div
$0.58
5Y div CAGR
91.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18955150364549300.00M
Annual income
$18,932,276,589,945,378,000,000.00
Full HWAFF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — HWAFF vs PFE

📍 HWAFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHWAFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HWAFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HWAFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HWAFF
Annual income on $10K today (after 15% tax)
$20,541.67/yr
After 10yr DRIP, annual income (after tax)
$16,092,435,101,453,570,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, HWAFF beats the other by $16,092,435,101,453,570,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HWAFF + PFE for your $10,000?

HWAFF: 50%PFE: 50%
100% PFE50/50100% HWAFF
Portfolio after 10yr
$9477575182274650.00M
Annual income
$9,466,138,294,972,689,000,000.00/yr
Blended yield
99.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HWAFF
No analyst data
Altman Z
6.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HWAFF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHWAFFPFE
Forward yield241.67%6.13%
Annual dividend / share$0.58$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR91.8%13.2%
Portfolio after 10y$18955150364549300.00M$49.6K
Annual income after 10y$18,932,276,589,945,378,000,000.00$26,258.71
Total dividends collected$18953650916156696.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HWAFF vs PFE ($10,000, DRIP)

YearHWAFF PortfolioHWAFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$57,052$46,351.67$9,153$693.39+$47.9KHWAFF
2$535,067$474,022.02$8,593$849.25+$526.5KHWAFF
3$8,541,515$7,968,992.49$8,336$1,066.78+$8.53MHWAFF
4$237,170,852$228,031,431.03$8,437$1,384.80+$237.16MHWAFF
5$11,603,514,258$11,349,741,446.91$9,013$1,875.40+$11603.51MHWAFF
6$1,007,773,094,032$995,357,333,775.79$10,306$2,680.72+$1007773.08MHWAFF
7$156,037,409,870,982$154,959,092,660,367.62$12,820$4,101.38+$156037409.86MHWAFF
8$43,174,823,007,642,776$43,007,862,979,080,824.00$17,673$6,826.70+$43174823007.63MHWAFF
9$21,377,359,442,919,993,000$21,331,162,382,301,815,000.00$27,543$12,591.86+$21377359442919.96MHWAFF
10$18,955,150,364,549,300,000,000$18,932,276,589,945,378,000,000.00$49,560$26,258.71+$18955150364549300.00MHWAFF

HWAFF vs PFE: Complete Analysis 2026

HWAFFStock

Hwa Fong Rubber (Thailand) Public Company Limited, together with its subsidiaries, manufactures and distributes tires and tubes in Thailand, rest of Asia, Europe, the United States, and internationally. The company operates in two segments, Sale of Goods and Services, and Investment. It offers tires and tubes for bicycles, motorcycles, and small logistics vehicles. The company markets its products under the DUNLOP, DURO, Q-UICK, and PREMIUM HFT trademarks. It is also involved in investing in bonds and securities; and the wholesale and retail trade of tires and tubes, and equipment. The company was founded in 1987 and is headquartered in Samutprakarn, Thailand. Hwa Fong Rubber (Thailand) Public Company Limited is a subsidiary of Hwa Fong Rubber Industries Company Limited.

Full HWAFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HWAFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HWAFF vs SCHDHWAFF vs JEPIHWAFF vs OHWAFF vs KOHWAFF vs MAINHWAFF vs JNJHWAFF vs MRKHWAFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.